Valuation: Amgen Inc.

Market Cap 223B 201B 187B 170B 319B 21,240B 321B 2,247B 878B 11,024B 838B 820B 35,455B P/E 2026 *
26.2x
P/E 2027 * 23.4x
Enterprise Value 265B 238B 222B 201B 378B 25,176B 380B 2,664B 1,040B 13,066B 993B 972B 42,025B EV / Sales 2026 *
6.79x
EV / Sales 2027 * 6.4x
Free-Float
99.77%
Yield 2026 *
2.44%
Yield 2027 * 2.58%
1 day+3.41%
1 week+3.39%
Current month+1.32%
1 month+11.95%
3 months+20.22%
6 months+21.70%
Current year+30.48%
1 week 400.06
Extreme 400.06
428.05
1 month 374.46
Extreme 374.46
428.05
Current year 318.21
Extreme 318.21
447.03
1 year 288
Extreme 288
447.03
3 years 249.7
Extreme 249.7001
447.03
5 years 198.64
Extreme 198.64
447.03
10 years 133.64
Extreme 133.64
447.03
Manager TitleAgeSince
Chief Executive Officer 63 30/04/2012
Director of Finance/CFO 62 12/05/2010
Chief Tech/Sci/R&D Officer 57 31/05/2023
Director TitleAgeSince
Chairman 63 31/12/2012
Director/Board Member 65 31/12/2011
Director/Board Member 71 31/12/2011
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Other

Chief Financial Officer

34,061 0.0063%
13/08/26 Exercice

Executive/Senior Manager

3,756 0.0007%
07/08/26 Free

Director

85 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+3.41%+3.39%+45.34%+48.87% 223B
+3.80%+1.90%+49.10%+96.43% 1,040B
+2.04%-1.90%+32.85%+60.95% 599B
+3.61%+4.75%+24.05%+93.06% 485B
+3.82%+3.18%+73.94%+41.47% 350B
+3.09%+3.03%+29.59%+47.09% 345B
+2.82%+2.20%+17.90%+40.67% 272B
+3.40%+0.99%-3.44%+12.10% 244B
+3.93%+4.55%+29.58%+93.85% 183B
-0.27%+0.81%-29.03%-63.79% 170B
Average +2.95%+2.59%+26.99%+47.07% 391.28B
Weighted average by Cap. +3.14%+2.40%+34.03%+62.36%

Financials

2026 *2027 *
Net sales 38.97B 35.04B 32.7B 29.64B 55.65B 3,709B 55.99B 392B 153B 1,925B 146B 143B 6,191B 40.39B 36.32B 33.89B 30.72B 57.67B 3,844B 58.03B 407B 159B 1,995B 152B 148B 6,417B
Net income 8.54B 7.68B 7.17B 6.49B 12.19B 813B 12.27B 86B 33.58B 422B 32.06B 31.37B 1,357B 9.43B 8.47B 7.91B 7.17B 13.46B 897B 13.54B 94.91B 37.06B 466B 35.39B 34.62B 1,497B
Net Debt 41.36B 37.18B 34.7B 31.45B 59.05B 3,936B 59.41B 416B 163B 2,043B 155B 152B 6,570B 35.48B 31.9B 29.77B 26.98B 50.65B 3,376B 50.97B 357B 139B 1,752B 133B 130B 5,636B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
14/10/26 US$427.12 +3.46% 1,463,276
13/10/26 US$412.84 -1.13% 2,319,612
12/10/26 US$417.57 +0.65% 1,720,680
09/10/26 US$414.87 +1.82% 2,553,179
08/10/26 US$407.44 -1.37% 2,378,286
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
412.84USD
Average target price
394.77USD
Spread / Average Target
-4.38%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.
  1. Stock Market
  2. Stocks
  3. AMGN Stock